# CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

> **NCT06117085** · NA · COMPLETED · sponsor: **Pulse Biosciences, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Thyroid Nodule (Benign)

## Interventions

- **DEVICE:** CellFX® Percutaneous Electrode (PE) System

## Key facts

- **NCT ID:** NCT06117085
- **Lead sponsor:** Pulse Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-13
- **Primary completion:** 2024-11-18
- **Final completion:** 2024-11-18
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06117085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06117085, "CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06117085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*